Aytu BioPharma, Inc. announced the Cotempla XR-ODT (Cotempla) bioequivalence study has been successfully completed. Accordingly, the Company expects to submit the Cotempla site transfer PAS to the FDA in the middle of calendar 2023, with approval expected thereafter. The Company expects a six-month review of the PAS, which would enable FDA approval by late calendar 2023 or early calendar 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.904 USD | +2.26% | +4.10% | +2.26% |
Feb. 14 | Transcript : Aytu BioPharma, Inc., Q2 2024 Earnings Call, Feb 14, 2024 | |
Feb. 14 | Earnings Flash (AYTU) AYTU BIOPHARMA Reports Q2 Revenue $22.9M, vs. Street Est of $21.75M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.26% | 16.17M | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- AYTU Stock
- News Aytu BioPharma, Inc.
- Aytu Biopharma, Inc. Announces Successfully Completion of Cotempla XR-ODT Bioequivalence Study